

Chordate Presents Interim Report with Q&A

On Thursday, August 31st, Chordate Medical will release its interim report for Q2 2023. On the same day at 2 PM, the company will hold a webcast presentation and Q&A session with CEO Anders Weilandt and Västra Hamnen Corporate Finance. The presentation will be conducted in Swedish and can be followed via computer or mobile devices.

To register for the web conference, please sign up using the following link: <https://attendee.gotowebinar.com/register/5303405709530509661>

The number of spots is limited, so we recommend registering well in advance to secure your spot.

A recording of the web conference will be available on the company's website www.chordate.com and on the Västra Hamnen Corporate Finance [YouTube channel](#) after the conference concludes.

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

[Chordate Presents Interim Report with Q&A](#)